Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342862 · ClinicalTrials.gov registry record
AMEVIVE® Pregnancy Registry
A clinical trial, sponsored by Astellas Pharma.
- Terminated
- Registry status
- 3
- Enrollment target
NCT00342862 is a clinical trial that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 3 participants.
The verdict
NCT00342862 was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVE® Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses exposed to AMEVIVE® in order to detect any potential increase in the risk of major birth defects. The AMEVIVE® Pregnancy Exposure Registry is sponsored by Astellas Pharma Global Development and will be managed by INC Research. The Registry will be monitored by an independent Advisory Committee of external experts in relevant specialties of teratology, epidemiology, maternal and fetal medicine, and infectious disease medicine (external member details available upon request).
Interventions
- DRUG Amevive exposure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2003-12 |
| Est. Completion | 2011-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00342862
The ClinicalTrials.gov registry entry for NCT00342862 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amevive exposure is the first listed.
NCT00342862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00342862 about?
NCT00342862 is a clinical study titled "AMEVIVE® Pregnancy Registry". This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVE® Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses exposed to AMEVIVE® in order to detect any potential increase in the risk of major birth defec...
What is the current status of trial NCT00342862?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2003-12. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00342862?
The interventions under investigation include: Amevive exposure (DRUG).
Who is sponsoring clinical trial NCT00342862?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.